Frontiers in Immunology (Nov 2023)

Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma

  • Yantao Ding,
  • Yantao Ding,
  • Yantao Ding,
  • Zhijie Zhao,
  • Huabao Cai,
  • Yi Zhou,
  • Yi Zhou,
  • Yi Zhou,
  • He Chen,
  • Yun Bai,
  • Zhenran Liu,
  • Shengxiu Liu,
  • Shengxiu Liu,
  • Shengxiu Liu,
  • Wenming Zhou,
  • Wenming Zhou,
  • Wenming Zhou

DOI
https://doi.org/10.3389/fimmu.2023.1304466
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundWe explore sphingolipid-related genes (SRGs) in skin melanoma (SKCM) to develop a prognostic indicator for patient outcomes. Dysregulated lipid metabolism is linked to aggressive behavior in various cancers, including SKCM. However, the exact role and mechanism of sphingolipid metabolism in melanoma remain partially understood.MethodsWe integrated scRNA-seq data from melanoma patients sourced from the GEO database. Through the utilization of the Seurat R package, we successfully identified distinct gene clusters associated with patient survival in the scRNA-seq data. Key prognostic genes were identified through single-factor Cox analysis and used to develop a prognostic model using LASSO and stepwise regression algorithms. Additionally, we evaluated the predictive potential of these genes within the immune microenvironment and their relevance to immunotherapy. Finally, we validated the functional significance of the high-risk gene IRX3 through in vitro experiments.ResultsAnalysis of scRNA-seq data identified distinct expression patterns of 4 specific genes (SRGs) in diverse cell subpopulations. Re-clustering cells based on increased SRG expression revealed 7 subgroups with significant prognostic implications. Using marker genes, lasso, and Cox regression, we selected 11 genes to construct a risk signature. This signature demonstrated a strong correlation with immune cell infiltration and stromal scores, highlighting its relevance in the tumor microenvironment. Functional studies involving IRX3 knockdown in A375 and WM-115 cells showed significant reductions in cell viability, proliferation, and invasiveness.ConclusionSRG-based risk signature holds promise for precise melanoma prognosis. An in-depth exploration of SRG characteristics offers insights into immunotherapy response. Therapeutic targeting of the IRX3 gene may benefit melanoma patients.

Keywords